[HTML][HTML] erbB in NSCLC as a molecular target: current evidences and future directions
ABSTRACT A number of treatments have been developed for HER1, 2 and 3-driven non-
small cell lung cancer (NSCLC), of which the most successful have been the epidermal …
small cell lung cancer (NSCLC), of which the most successful have been the epidermal …
Comparison of T790M acquisition after treatment with first-and second-generation tyrosine-kinase inhibitors: A systematic review and network meta-analysis
PC Hsieh, YK Wu, CY Huang, MC Yang, CY Kuo… - Frontiers in …, 2022 - frontiersin.org
Background Lung adenocarcinoma is a common disease with a high mortality rate.
Epidermal growth factor receptor (EGFR) mutations are found in adenocarcinomas, and oral …
Epidermal growth factor receptor (EGFR) mutations are found in adenocarcinomas, and oral …
Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA
JD Finkle, H Boulos, TM Driessen, C Lo… - NPJ Precision …, 2021 - nature.com
Liquid biopsy is a valuable precision oncology tool that is increasingly used as a non-
invasive approach to identify biomarkers, detect resistance mutations, monitor disease …
invasive approach to identify biomarkers, detect resistance mutations, monitor disease …
[HTML][HTML] Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from …
M Provencio, R Serna-Blasco, F Franco, V Calvo… - European Journal of …, 2021 - Elsevier
Background Survival data support the use of first-line osimertinib as the standard of care for
epidermal growth factor receptor (EGFR)–positive non-small cell lung cancer (NSCLC) …
epidermal growth factor receptor (EGFR)–positive non-small cell lung cancer (NSCLC) …
An easy method for pressure measurement in microchannels using trapped air compression in a one-end-sealed capillary
F Shen, M Ai, J Ma, Z Li, S Xue - Micromachines, 2020 - mdpi.com
Pressure is one basic parameter involved in microfluidic systems. In this study, we
developed an easy capillary-based method for measuring fluid pressure at one or multiple …
developed an easy capillary-based method for measuring fluid pressure at one or multiple …
Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective …
X Wang, J Cai, Z Zeng, A Liu - BMC cancer, 2021 - Springer
Background Leptomeningeal metastasis (LM) is a severe complication of advanced non-
small cell lung cancer (NSCLC). This retrospective study aimed to investigate the potential …
small cell lung cancer (NSCLC). This retrospective study aimed to investigate the potential …
[HTML][HTML] T790M detection rate after first-line combination therapy with bevacizumab and EGFR-TKIs in advanced NSCLC (TERRA Study)
CHS Kuo, PL Su, YF Wei, JC Ko, JS Tseng… - American Journal of …, 2023 - ncbi.nlm.nih.gov
Real-world data regarding the T790M mutation rate after acquiring resistance to first-line
combination therapy with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR …
combination therapy with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR …
Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non–small-cell lung cancer: a propensity-matched …
X Wang, Z Zeng, J Cai, P Xu, P Liang, Y Luo, A Liu - BMC cancer, 2021 - Springer
Background This retrospective study aimed to evaluate the efficacy of epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with stereotactic body radiation …
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with stereotactic body radiation …
Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC
J Lu, X Ji, X Liu, Y Jiang, G Li, P Fang, W Li, A Zuo… - Scientific Reports, 2024 - nature.com
The epidermal growth factor receptor (EGFR) Thr790 Met (T790M) mutation is responsible
for approximately half of the acquired resistance to EGFR-tyrosine kinase inhibitor (TKI) in …
for approximately half of the acquired resistance to EGFR-tyrosine kinase inhibitor (TKI) in …
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact …
G Pasello, M Lorenzi, D Scattolin, A Del Conte… - The …, 2024 - academic.oup.com
Introduction The observational multicenter prospective FLOWER study (NCT04965701)
confirmed effectiveness and safety of osimertinib in the real-world (RW) management of …
confirmed effectiveness and safety of osimertinib in the real-world (RW) management of …